Top Adderall Brands for Efficacy and Trustworthiness

In recent years, the demand for Adderall, a medication primarily prescribed for attention deficit hyperactivity disorder (ADHD), has led to increased scrutiny of the brands that manufacture it. Various pharmaceutical companies have made a name for themselves by producing high-quality, effective versions of this drug. Patients and healthcare providers often seek out the most reputable brands to ensure efficacy and safety, taking into account factors like availability and patient reviews. For an in-depth look at some of the best brands for Adderall currently on the market, see the comprehensive list below.

Illustration of adderall

Best brands of adderall in 2025

Teva Pharmaceuticals

Teva Pharmaceuticals, a major global pharmaceutical company, is a significant producer of Adderall, a medication used to treat ADHD, and while they experienced manufacturing delays in 2022, they are currently producing at levels consistent with historic norms, despite an unprecedented demand. Though Teva's branded Adderall products are currently available, some of their generic versions, like the 5mg, are still experiencing shortages, which is part of a broader shortage in the ADHD medication market. In 2021, Teva sold over half a billion dollars worth of Adderall, making them a leading supplier in the US market.

Barr Pharmaceuticals

Barr Pharmaceuticals, established as the first manufacturer of a generic Adderall equivalent, began developing their version in 1998 and launched it in February 2002 after FDA approval, ensuring it was both safe and effective, and the product was deemed therapeutically equivalent to the brand name version. Despite initial lawsuits from Shire, the original Adderall manufacturer, Barr secured a significant share of the market by 2005, and in 2006, Barr acquired the rights to the immediate-release Adderall product from Shire, demonstrating their strong position in the generic stimulant market; further solidifying their position, Barr reached a settlement with Shire in 2009, allowing them to launch a licensed generic version of Adderall XR. You can find more information about Barr products.

Shire Pharmaceuticals

While Shire Pharmaceuticals played a pivotal role in the development and marketing of Adderall, it's essential to understand its current role and historical context. Shire, acquired by Takeda in 2019, initially launched Adderall (amphetamine and dextroamphetamine) and later Adderall XR, achieving a 23.8% market share in 2003. Although Shire developed and received FDA approval for Adderall in 1996 and Adderall XR in 2001, the company divested the immediate release version (Adderall IR) in 2007. Currently, Shire, under Takeda, manufactures only the extended-release version, Adderall XR, which held a 25.5% market share in 2007 after introduction. Despite past market dominance, Shire no longer manufactures Adderall IR, with companies like Teva emerging as a primary manufacturer of the generic version, while Takeda continues to produce Adderall XR.

Prasco Laboratories

Prasco Laboratories, a privately held pharmaceutical company founded in 2002, is a key player in the authorized generic market, distributing generic versions of brand-name drugs, including Adderall XR; in 2016, Prasco acquired the rights to distribute an authorized generic version of Adderall XR, and in 2023 they partnered with Elite Pharmaceuticals to distribute generic Adderall XR, with Prasco marketing it under Burel Pharmaceutical's label, ensuring consistent availability in over 60,000 US pharmacies; despite some market fluctuations, Prasco remains a significant distributor of this medication, providing quality options for patients. You can find more information about their products on their website.

Elite Pharmaceuticals

Elite Pharmaceuticals is a specialty pharmaceutical company that develops and manufactures generic medications, including a generic version of Adderall, which is a central nervous system stimulant used to treat ADHD and Narcolepsy. In 2019, the FDA approved their generic Adderall XR, and in 2023, they began shipping this product to Prasco, LLC for distribution, while they also received approval from the Israeli Ministry of Health for their immediate-release generic Adderall in 2024. Elite's generic Adderall is available in various strengths, including 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg, and 30mg. They co-own their generic Adderall products with Mikah Pharma LLC, and they also have partnered with other companies like SunGen Pharma for development and distribution, highlighting their role as a key player in the generic pharmaceutical market. For more information about Elite Pharmaceuticals and their products, visit their website.

Zydus Pharmaceuticals

Zydus Pharmaceuticals, a significant producer of generic Adderall, received USFDA approval in 2019 to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate extended-release capsules, available in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg dosages. Despite facing supply and pricing issues, Zydus remains a key player in the market, with their generic version of Adderall XR manufactured at their facility in St. Louis, MO. Although a drug shortage occurred in 2022, their products are still readily available. For more information about their products, you can visit their website.

Lannett Company

Lannett Company, established in 1942, is a significant producer of generic Adderall, offering both immediate-release (IR) and extended-release (XR) versions, with the IR tablets available in 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg, and 30mg strengths, and the XR capsules in 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg strengths. While the estimated market value for Adderall XR generics was about $1.3 billion for the 12 months ending January 2020, Lannett acts as the exclusive U.S. distributor through a partnership with Elite Pharmaceuticals and SunGen Pharma, despite multiple generic suppliers in the market. The company's generic Adderall IR was launched in their fiscal year 2019 fourth quarter, and the generic Adderall XR was launched in March 2020, contributing to their wide range of generic pharmaceutical products. For more information about the product, visit their website.

Alvogen Inc.

Alvogen Inc., established in 2009, is a significant pharmaceutical company that produces generic medications, including various dosages of amphetamine mixed salts, a generic form of Adderall. While facing intermittent backorders for some dosages like 5mg, 20mg, and 30mg, they continue to release supplies as they become available, with 10mg tablets available to contracted customers and 15mg in limited supply. The increased demand for ADHD medications in recent years has contributed to supply challenges across the industry. Despite these challenges, Alvogen remains a key player in the production of generic Adderall. For more information on Alvogen's products and services, you can visit their website.

Actavis

While Actavis was a significant player in the pharmaceutical industry and produced a generic version of Adderall, it's important to note that Actavis was acquired by Teva in 2016, and it no longer operates as a separate entity. Actavis received FDA approval for its generic Adderall XR in 2012, contributing to the market with various strengths of the medication, and before the acquisition, Actavis, Teva, and Watson shared approximately 61% of the market for the product. However, the brand name Adderall is associated with Shire, and Teva now manufactures both brand-name and generic versions of Adderall and is a major supplier in the US, despite facing manufacturing delays in recent years which led to shortages. For more information on Teva's Adderall products, you can visit their website.

Aurobindo Pharma

Aurobindo Pharma, established in 1986, is a significant producer of generic Adderall, an amphetamine mixed salts medication used for ADHD, with FDA approval for various strengths such as 10mg, 15mg, and 20mg tablets. Despite facing some manufacturing challenges and recalls in the past, they have a strong market presence, particularly in the US, where 48% of their revenue comes from. They continue to supply this medication even during recent shortages, as one of the 5 pharmaceutical companies affected by the FDA declared shortage in 2019, resolved by 2022. It is important to note that there have been some quality control issues cited by the FDA related to API testing at their facilities.